Vir Biotechnology Reports Positive Data in Ongoing Trials for VIR-5818 and VIR-5500 Vir Biotechnology, Inc. (Nasdaq: VIR) has presented encouraging preliminary Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets HER2-expressing solid tumors, and VIR-5500,…
Nalu PNS System Cuts Healthcare Costs for Chronic Pain Patients Nalu Medical, Inc., a prominent leader in peripheral nerve stimulation (PNS), recently announced the publication of a study in Pain Management journal that demonstrates the significant healthcare cost savings associated…
GeneDx Advances Genomics Research, Impacting Over 22,000 Patients GeneDx (Nasdaq: WGS), a pioneer in genomic insights for improved health outcomes, continues to make significant strides in advancing scientific research, especially in the area of gene-disease relationships. In 2024 alone, the…
Diabetes Insulin Dosing Enhanced Through Hedia and Glooko Partnership Glooko, Inc. and Hedia have launched an innovative interoperable solution designed to improve diabetes management. The solution integrates connected care, remote patient monitoring, and digital therapeutic technologies to provide enhanced support…
Eye on 2025: Viridian Sets Priorities After Positive Phase 3 TED Data Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company committed to developing potential best-in-class treatments for serious and rare diseases, has outlined its corporate priorities and upcoming catalysts for…
Approval of Merck’s GARDASIL® Expanded for Males in China Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that the National Medical Products Administration (NMPA) of China has approved GARDASIL® (Human Papillomavirus Quadrivalent Vaccine, Recombinant)…
Cancer Treatment Localization: Boston Oncology Arabia & SPIMACO Partner in Saudi Arabia In a groundbreaking move to enhance cancer care in the Middle East, Boston Oncology Arabia and SPIMACO have formalized their collaboration through a Memorandum of Understanding (MoU) aimed…
Phase 3 Studies for Azafaros Receive Key Regulatory Approvals, Set to Begin in 2025 Azafaros B.V. today revealed that its leading asset, nizubaglustat, has received Orphan Drug Designation (ODD) from both U.S. and European regulatory authorities for the treatment of…
QIAGEN Backs UK Initiative to Sequence 100,000 Newborn Genomes QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has announced a strategic partnership with Genomics England to support the ambitious Generation Study, a groundbreaking initiative aiming to sequence the genomes of 100,000…
Partnering for Bispecific Antibodies and ADCs: Biocytogen and Acepodia Biocytogen (HKEX: 02315) and Acepodia (6976:TT) have announced a strategic partnership aimed at jointly evaluating a dual-payload bispecific antibody-drug conjugate (BsAD2C) program. This collaboration marks a significant step forward in their…
Wearable Data Integrated into EHR for Personalized Care by Validic At CES, Validic, a leader in digital health and personalized care technology, unveiled a new integration of physical activity data from wearables and smartwatches into electronic health record (EHR) systems.…
Viz.ai Partners with 3 Pharma Companies, Expands to 60,000 Providers Viz.ai, a leader in AI-powered disease detection and care coordination, has announced major achievements in its mission to revolutionize healthcare delivery. In 2024, the company formed partnerships with three of…